RTP Mobile Logo
Select Publications

Gonzalvez F. TAK-788: An EGFR inhibitor, currently in Phase II clinical trials, targeting lung cancers with Exon20 insertion mutations. AACR 2020. Abstract

Herbst RS et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. ASCO 2020;Abstract LBA5.

Nakagawa K et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(12):1655-69. Abstract

Park K et al. Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). ASCO 2020;Abstract 9512.

Piotrowska Z et al. ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. ASCO 2020;Abstract 9513.

Ramalingam SS et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382(1):41-50. Abstract

Ramalingam SS et al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. ESMO 2018;Abstract LBA50.

Reungwetwattana T et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018;JCO2018783118. Abstract

Sequist LV et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study. Lancet Oncol 2020;21(3):373-86. Abstract

Soria JC et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113-25. Abstract

Wu YL et al. CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation — Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. ASCO 2020;Abstract 9005.

Yasuda H et al. EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol 2012;13(1):e23-31. Abstract